Emergent Biosolutions (EBS) has issued an announcement.
Emergent BioSolutions Inc. has announced a deal to sell its Baltimore-Camden drug product facility to Bora Pharmaceuticals Injectibles Inc. for approximately $30 million. The agreement will also see around 350 employees transition to Bora Pharmaceuticals. The successful completion of the sale hinges on standard closing conditions and the maintenance of the facility’s operations until the closure of the deal, which is anticipated by September 30, 2024, unless otherwise terminated by the parties involved.
Find detailed analytics on EBS stock on TipRanks’ Stock Analysis page.
